NCT05659953View on ClinicalTrials.gov

LMT503 First-in-human SAD, MAD, and FE Study

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

October 1, 2025

Study Completion Date

March 1, 2026

Conditions
Inflammatory Bowel DiseaseColitis, UlcerativeCrohn Disease
Interventions
DRUG

LMT503

Subjects will receive one of several different oral doses of LMT503 once daily

DRUG

Placebo

Subjects will receive one of several different oral doses of Placebo once daily

Trial Locations (1)

9728

ICON plc Company - Early Development Services, Groningen

Sponsors
All Listed Sponsors
lead

Lmito Therapeutics Inc.

INDUSTRY